Logo image of YS

YS BIOPHARMA CO LTD (YS) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:YS - KYG9845F1090 - Common Stock

1.02 USD
+0.11 (+12.45%)
Last: 5/24/2024, 8:06:00 PM
1.07 USD
+0.05 (+4.9%)
After Hours: 5/24/2024, 8:06:00 PM
Fundamental Rating

2

Taking everything into account, YS scores 2 out of 10 in our fundamental rating. YS was compared to 534 industry peers in the Biotechnology industry. YS has a bad profitability rating. Also its financial health evaluation is rather negative. YS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year YS has reported negative net income.
YS Yearly Net Income VS EBIT VS OCF VS FCFYS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 -50M -100M -150M -200M -250M

1.2 Ratios

Looking at the Return On Assets, with a value of -17.59%, YS belongs to the top of the industry, outperforming 83.77% of the companies in the same industry.
YS has a Return On Equity of -50.88%. This is in the better half of the industry: YS outperforms 66.32% of its industry peers.
Industry RankSector Rank
ROA -17.59%
ROE -50.88%
ROIC N/A
ROA(3y)-6.91%
ROA(5y)N/A
ROE(3y)-18.75%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
YS Yearly ROA, ROE, ROICYS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 -10 -20 -30

1.3 Margins

Looking at the Gross Margin, with a value of 77.68%, YS belongs to the top of the industry, outperforming 86.18% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for YS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 77.68%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
YS Yearly Profit, Operating, Gross MarginsYS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 0 20 -20 40 -40 60

More info and screens

1

2. Health

2.1 Basic Checks

YS does not have a ROIC to compare to the WACC, probably because it is not profitable.
YS has more shares outstanding than it did 1 year ago.
The debt/assets ratio for YS is higher compared to a year ago.
YS Yearly Shares OutstandingYS Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 20M 40M 60M 80M
YS Yearly Total Debt VS Total AssetsYS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 500M 1B 1.5B

2.2 Solvency

Based on the Altman-Z score of -0.65, we must say that YS is in the distress zone and has some risk of bankruptcy.
YS has a Altman-Z score of -0.65. This is comparable to the rest of the industry: YS outperforms 56.82% of its industry peers.
YS has a Debt/Equity ratio of 0.65. This is a neutral value indicating YS is somewhat dependend on debt financing.
The Debt to Equity ratio of YS (0.65) is worse than 75.30% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.65
Debt/FCF N/A
Altman-Z -0.65
ROIC/WACCN/A
WACC7.73%
YS Yearly LT Debt VS Equity VS FCFYS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 200M -200M 400M 600M

2.3 Liquidity

YS has a Current Ratio of 1.41. This is a normal value and indicates that YS is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of YS (1.41) is worse than 83.77% of its industry peers.
A Quick Ratio of 1.09 indicates that YS should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.09, YS is doing worse than 86.18% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.41
Quick Ratio 1.09
YS Yearly Current Assets VS Current LiabilitesYS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 200M 400M 600M 800M 1B

More info and screens

3

3. Growth

3.1 Past

YS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -9348.42%.
EPS 1Y (TTM)-9348.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-946.42%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

YS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 27.80% yearly.
YS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 85.19% yearly.
EPS Next Y19.72%
EPS Next 2Y31.7%
EPS Next 3Y27.8%
EPS Next 5YN/A
Revenue Next Year-6.61%
Revenue Next 2Y9.01%
Revenue Next 3Y27.69%
Revenue Next 5Y85.19%

3.3 Evolution

YS Yearly Revenue VS EstimatesYS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 500M 1B 1.5B 2B 2.5B
YS Yearly EPS VS EstimatesYS Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 0 -0.1 -0.2 -0.3

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for YS. In the last year negative earnings were reported.
Also next year YS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
YS Price Earnings VS Forward Price EarningsYS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
YS Per share dataYS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4

4.3 Compensation for Growth

A more expensive valuation may be justified as YS's earnings are expected to grow with 27.80% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.7%
EPS Next 3Y27.8%

More info and screens

0

5. Dividend

5.1 Amount

YS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

YS BIOPHARMA CO LTD

NASDAQ:YS (5/24/2024, 8:06:00 PM)

After market: 1.07 +0.05 (+4.9%)

1.02

+0.11 (+12.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-19 2024-04-19/bmo
Earnings (Next)N/A N/A
Inst Owners1.72%
Inst Owner Change-23.27%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap192.10M
Revenue(TTM)687.20M
Net Income(TTM)-283.47M
Analysts84.44
Price Target4.26 (317.65%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.47%
PT rev (3m)-19.32%
EPS NQ rev (1m)0%
EPS NQ rev (3m)26.45%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.98%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-85.12%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.02
P/FCF N/A
P/OCF N/A
P/B 2.5
P/tB 2.88
EV/EBITDA N/A
EPS(TTM)-0.42
EYN/A
EPS(NY)-0.02
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.5
BVpS0.41
TBVpS0.35
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -17.59%
ROE -50.88%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 77.68%
FCFM N/A
ROA(3y)-6.91%
ROA(5y)N/A
ROE(3y)-18.75%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.43
Health
Industry RankSector Rank
Debt/Equity 0.65
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.41
Quick Ratio 1.09
Altman-Z -0.65
F-ScoreN/A
WACC7.73%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-9348.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-946.42%
EPS Next Y19.72%
EPS Next 2Y31.7%
EPS Next 3Y27.8%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-6.61%
Revenue Next 2Y9.01%
Revenue Next 3Y27.69%
Revenue Next 5Y85.19%
EBIT growth 1Y-24931.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-18.13%
EBIT Next 3Y41.56%
EBIT Next 5YN/A
FCF growth 1Y-38958.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-29655.5%
OCF growth 3YN/A
OCF growth 5YN/A

YS BIOPHARMA CO LTD / YS FAQ

What is the fundamental rating for YS stock?

ChartMill assigns a fundamental rating of 2 / 10 to YS.


What is the valuation status of YS BIOPHARMA CO LTD (YS) stock?

ChartMill assigns a valuation rating of 1 / 10 to YS BIOPHARMA CO LTD (YS). This can be considered as Overvalued.


Can you provide the profitability details for YS BIOPHARMA CO LTD?

YS BIOPHARMA CO LTD (YS) has a profitability rating of 2 / 10.


What is the earnings growth outlook for YS BIOPHARMA CO LTD?

The Earnings per Share (EPS) of YS BIOPHARMA CO LTD (YS) is expected to grow by 19.72% in the next year.